Pravastatin
Pravastatin has been studied in 70 papers since 1993: 15 trials and 19 observational studies in people, 11 in animals, 7 in cells, 15 reviews; 26 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “Cardiovascular Effects of a Broad Range of Interventions for Adults with Prediabetes: A Systematic Review of Randomized Controlled Trials”.
InterventionStatinsApproved 1991
70 papers study it22 more mention it56 findingsUpdated
5 new papers in 30 daysSee all 90 papers on pravastatin
At a glance
Human trials report lower mortality with pravastatin, replicated by independent labs, but others show no clear mortality benefit; a trial reports shorter survival in adults 65 and older without cardiovascular disease. Independent human studies report cholesterol reductions but disagree on coenzyme Q10. Some authors have company affiliations, papers declare company ties, and Bristol Myers Squibb sponsors some registered trials.
56 findings in 27 papers from 1993 to 2026, 4 of them since July 2026
Independent labs found the same change in cells and people. 27 independent labs in 14 countries; 95 trials, 6 about aging, 55 with no results posted.
“the risk ratio was 0.79 (0.68, 0.91) for death”
7 of its findings point the other way.
- 27 independent labs in 14 countries
- 7 findings against
- 95 trials, 6 about aging, 55 with no results posted
- Funders: Bristol Myers Squibb and others
- 8 of 57 findings with company ties
- 7 of 95 trials sponsored by its developers
- Human trial15
- Humans19
- Animals10
- Cells7
- In silico2
Studies in people
See all 11 studies of pravastatin in people11 studies gave pravastatin to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Protects against mortalityRR 0.79 (0.68, 0.91), risk difference -3.0% (-4.9%, -1.3%) | Randomized trial5 year | 9,741 people≥55 years oldMidlife adults; Older adults; moderately hypercholesterolemic, hypertensive, under full adherence | American journal of epidemiology, Mar 6, 2026 |
| Randomized trial3.2 years | 5,749 people70–82 yearsOlder population with a history or increased risk of CVD | JHEP reports : innovation in hepatology, Feb 7, 2025 | |
down: Lowers the risk of strokeHR .93; 95% CI .22–3.91 no change: Has no effect on cardiovascular disease | Randomized trialmean follow‐up of 3.2 years (range: 2.8–4.0) | 5,804 peopleaged 70–82Elderly individuals at risk of vascular disease | European journal of clinical investigation, Dec 5, 2024 |
down: Decreases bone attenuation-2.6% vs 0% median change (atorvastatin) | Randomized trial12 months | 420 peopleWomenPostmenopausal women; Patient cohorts | Atherosclerosis, Dec 12, 2023 |
down: Decreases cardiovascular events-78 events per 10 000 person-years (95% CI, -144 to -12) | Randomized trial | 2,891 people70-82 yearsOlder adults; prescribing pravastatin to all participants | European journal of preventive cardiology, Dec 12, 2023 |
What did lifespan studies of pravastatin find?
DrugAgeDrugAge records 1 result from 1 paper: 1 in B. manjavacas. Average lifespan is the mean or the median, as each paper reports it.
What did studies of pravastatin find?
40Studies of pravastatin measured 40 outcomes; the most studied are coenzyme Q10 (4 studies), mortality (2) and cell proliferation (2).
Coenzyme Q10
no changein humans2downin humans2−40% reduction
4 studies
Coenzyme Q10
no changein humans2downin humans2−40% reduction
Pravastatin showed no clear effect on coenzyme Q10 in humans (0.61 +/- 0.14 vs 0.62 +/- 0.2 microg/mL, P >.05).
“There was no difference in CoQ10 levels from baseline to post-drug therapy for either P or A”
Human trial20 mg4 weeks
The effect of pravastatin and atorvastatin on coenzyme Q10
American heart journal
Pravastatin decreases coenzyme Q10 in humans (hypercholesterolemia) (from 1.27 +/- 0.34 to 1.02 +/- 0.31 mmol/l, P < 0.01).
“A dose-related significant decline of the total serum level of coenzyme Q10 was found in the pravastatin group from 1.27 +/- 0.34 at baseline to 1.02 +/- 0.31 mmol/l”
Human trialhypercholesterolemia10-40 mg/day18 weeks
Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors
Molecular aspects of medicine
Pravastatin decreases coenzyme Q10 in humans (hypercholesterolemia; compared with placebo) (About 40% reduction).
“The same extent of reduction, compared with placebo was measured in hypercholesterolemic patients treated with pravastatin or simvastatin.”
Human trialhypercholesterolemia; compared with placeboplasma20 mg/day3 monthsn = 30
Journal of clinical pharmacology
Pravastatin was not clearly linked with coenzyme Q10 in humans (coronary artery disease).
“it did not improve either the ubiquinone level or the LDL/ubiquinone ratio.”
Humanscoronary artery diseaseplasma
Coenzyme Q10 and coronary artery disease
The Clinical investigator
Mortality
downin humans1no changein humans1RR 0.79
2 studies
Mortality
downin humans1no changein humans1RR 0.79
Pravastatin protects against mortality in humans (moderately hypercholesterolemic, hypertensive, under full adherence) (RR 0.79 (0.68, 0.91), risk difference -3.0% (-4.9%, -1.3%)).
“the risk ratio was 0.79 (0.68, 0.91) for death”
Human trialmoderately hypercholesterolemic, hypertensive, under full adherence40 mg/day5 yearn = 9,741
Trial reanalysis links pravastatin adherence to fewer deaths
American journal of epidemiology
Pravastatin showed no clear effect on mortality in humans (HR 1.18 (95% CI 0.97-1.42)).
“The hazard ratios for all-cause mortality in the pravastatin group vs the UC group were 1.18 (95% CI, 0.97-1.42; P = .09) for all adults 65 years and older”
Human trial40 mg/dn = 2,867
JAMA internal medicine
Cell proliferation
downin cells1downin human cells1
2 studies
Cell proliferation
downin cells1downin human cells1
Pravastatin decreases cell proliferation in cystic cholangiocytes in culture.
“It also normalized mitochondrial hyperactivity and reduced the proliferation of cystic cholangiocytes in culture”
Cellsin cystic cholangiocytes in culture
Hepatology (Baltimore, Md.)
Pravastatin inhibits cell proliferation in human cells (senescent cells).
“selectively inhibits the proliferation of senescent cells”
Cellssenescent cellslung fibroblast
Selective Growth Suppressive Effect of Pravastatin on Senescent Human Lung Fibroblasts
Die Pharmazie
Low-density lipoprotein cholesterol
downin humans2
2 studies
Low-density lipoprotein cholesterol
downin humans2
Pravastatin decreases low-density lipoprotein cholesterol in humans (109.1 vs 128.8 mg/dL at year 6).
“by year 6, the mean (SD) low-density lipoprotein cholesterol levels were 109.1 (35.4) mg/dL in the pravastatin group and 128.8 (27.5) mg/dL in the UC group.”
Human trial40 mg/dyear 6
JAMA internal medicine
Pravastatin decreases low-density lipoprotein cholesterol in humans (97 +/- 21 vs 66 +/- 19 mg/dL, P <.01).
“There was a significant difference in low-density lipoprotein (LDL) levels from baseline to post-drug therapy for both P and A”
Human trial20 mg4 weeks
The effect of pravastatin and atorvastatin on coenzyme Q10
American heart journal
Total cholesterol
downin humans2−40% reduction
2 studies
Total cholesterol
downin humans2−40% reduction
Pravastatin decreases total cholesterol in humans (hypercholesterolemia; compared with placebo) (About 40% reduction).
“The same extent of reduction, compared with placebo was measured in hypercholesterolemic patients treated with pravastatin or simvastatin.”
Human trialhypercholesterolemia; compared with placeboplasma20 mg/day3 monthsn = 30
Journal of clinical pharmacology
Pravastatin is linked with lower total cholesterol in humans (coronary artery disease).
“The present study revealed that HMG CoA reductase inhibitor decreased plasma cholesterol level”
Humanscoronary artery diseaseplasma
Coenzyme Q10 and coronary artery disease
The Clinical investigator
TLR4 signaling
downin rats1
1 study
TLR4 signaling
downin rats1
Pravastatin inhibits TLR4 signaling in rats (excessive hypercholesterolemia in pregnancy).
“In uterine arteries, pravastatin improved blood flow and endothelial function mainly via suppression of TLR4”
Animalsexcessive hypercholesterolemia in pregnancyuterine artery5 mg/kg/dayGD10-20females
Clinical science (London, England : 1979)
Carotid artery endothelial function
no changein rats1
1 study
Carotid artery endothelial function
no changein rats1
Pravastatin showed no clear effect on carotid artery endothelial function in rats (excessive hypercholesterolemia in pregnancy).
“In carotid arteries, endothelial function was unchanged;”
Animalsexcessive hypercholesterolemia in pregnancycarotid artery5 mg/kg/dayGD10-20females
Clinical science (London, England : 1979)
Uterine artery endothelial function
upin rats1
1 study
Uterine artery endothelial function
upin rats1
Pravastatin improves uterine artery endothelial function in rats (excessive hypercholesterolemia in pregnancy).
“In uterine arteries, pravastatin improved blood flow and endothelial function mainly via suppression of TLR4, while also increasing nitric oxide-mediated vasodilation.”
Animalsexcessive hypercholesterolemia in pregnancyuterine artery5 mg/kg/dayGD10-20females
Clinical science (London, England : 1979)
Colony formation
downin human cells1
1 study
Colony formation
downin human cells1
Pravastatin decreases colony formation in human cells (primary human DNMT3A R882-mutant PBMCs relative to wild-type).
“In vitro, pravastatin selectively suppressed colony formation of primary human DNMT3A R882-mutant relative to wild-type cells (P=0.031).”
Cellsprimary human DNMT3A R882-mutant PBMCs relative to wild-typeperipheral blood mononuclear cell
medRxiv : the preprint server for health sciencesPreprint
CAV1
upin human cells1
1 study
CAV1
upin human cells1
Pravastatin increases CAV1 in uterine radial arteries from preeclamptic pregnancies.
“Myoendothelial gap junction and endothelial caveolae density, and caveolin-1 and endothelial-NOS expression were decreased in arteries from PE relative to NT pregnancies and increased following pravastatin incubation.”
Cellsin uterine radial arteries from preeclamptic pregnanciesuterine radial artery2 mM6 h
Pravastatin Corrects Endothelial Dysfunction in Ex Vivo Uterine Radial Arteries in Preeclampsia
Acta physiologica (Oxford, England)
Cardiovascular disease
no changein humans1
1 study
Cardiovascular disease
no changein humans1
Pravastatin showed no clear effect on cardiovascular disease in elderly subjects with obesity and liver fibrosis.
“Pravastatin did not affect other cardiovascular endpoints in elderly subjects with obesity and liver fibrosis.”
Human trialin elderly subjects with obesity and liver fibrosismean follow‐up of 3.2 years (range: 2.8–4.0)
European journal of clinical investigation
Bone attenuation
downin humans1
1 study
Bone attenuation
downin humans1
Pravastatin decreases bone attenuation in humans (compared with atorvastatin 80 mg/day) (-2.6% vs 0% median change (atorvastatin)).
“At follow-up, the median bone attenuation loss was significantly greater with PRV than with ATV [-2.6 (-27 to 11)% vs 0 (-11 to 25)%; p < 0.001].”
Human trialcompared with atorvastatin 80 mg/daythoracic vertebrae40 mg/day12 monthsfemalesn = 420
Atherosclerosis
Cardiovascular events
downin humans1
1 study
Cardiovascular events
downin humans1
Pravastatin decreases cardiovascular events in humans (prescribing pravastatin to all participants) (-78 events per 10 000 person-years (95% CI, -144 to -12)).
“-78 events (95% CI, -144 to -12) when prescribing pravastatin to all participants”
Human trialprescribing pravastatin to all participantsn = 2,891
European journal of preventive cardiology
Coronary artery disease
no changein humans1
1 study
Coronary artery disease
no changein humans1
Pravastatin showed no clear effect on coronary artery disease in humans (primary prevention in adults 65+ free of cardiovascular disease) (+18.7 days CHD-free survival, 95% CI -10.4 to 47.8, p=.21).
“18.7 more days free of CHD over 6 years than those receiving usual care (RMST 2,069.4 days), but this difference was not statistically significant (difference 18.7 days, 95% CI=-10.4-47.8 days, p=.21)”
Human trialprimary prevention in adults 65+ free of cardiovascular disease40 mg/d6 yearsn = 2,867
Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis
Journal of the American Geriatrics Society
Survival
downin humans1
1 study
Survival
downin humans1
Pravastatin decreases survival in humans (primary prevention in adults 65+ free of cardiovascular disease) (-33.7 days, 95% CI -67.0 to -0.5, p=.047).
“individuals treated with pravastatin lived (RMST 2,008.1 days), on average, 33.7 fewer days than those receiving usual care (RMST 2,041.8 days) (difference -33.7 days, 95% confidence interval (CI)=-67.0 to -0.5 days, p=.047)”
Human trialprimary prevention in adults 65+ free of cardiovascular disease40 mg/d6 yearsn = 2,867
Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis
Journal of the American Geriatrics Society
All 40Fewer
What is pravastatin linked with?
7Studies link pravastatin with 7 measures, among them mortality, stroke and cardiovascular events.
Mortality
downin humans1
1 study
Mortality
downin humans1
Pravastatin lowers the risk of mortality in humans (depending on FIB-4 classification).
“The interaction term between FIB-4 class and statin treatment was significant (p = 0.049), indicating that the effect of treatment depended on FIB-4 classification (or vice versa).”
Human trialdepending on FIB-4 classification3.2 years
JHEP reports : innovation in hepatology
Pravastatin lowers the risk of mortality in humans (high FIB-4 classification) (interaction p = 0.049).
“In the pravastatin group, the HR for all-cause mortality was not associated with FIB-4 classification: high-class HR = 1.01 (95% CI, 0.69-1.49).”
Human trialhigh FIB-4 classification
JHEP reports : innovation in hepatology
Stroke
downin humans1
1 study
Stroke
downin humans1
Pravastatin lowers the risk of stroke in elderly subjects with obesity and liver fibrosis (HR .93; 95% CI .22–3.91).
“In the group on pravastatin, no increased risk was present for that group (HR.93; 95% CI.22–3.91).”
Human trialin elderly subjects with obesity and liver fibrosismean follow‐up of 3.2 years (range: 2.8–4.0)
European journal of clinical investigation
Pravastatin lowers the risk of stroke in humans (high FIB-4 and obesity).
“Elderly individuals with obesity and liver fibrosis are at higher risk for (non-)fatal stroke, which is reduced with pravastatin.”
Human trialhigh FIB-4 and obesity
European journal of clinical investigation
Cardiovascular events
downin humans1RR 0.81
1 study
Cardiovascular events
downin humans1RR 0.81
Pravastatin lowers the risk of cardiovascular events in humans (Prediabetes with a history of myocardial infarction or unstable angina) (RR 0.81, 95% CI 0.70–0.95, p = 0.008).
“pravastatin significantly reduced cardiovascular events in patients with prediabetes with a history of myocardial infarction or unstable angina”
ReviewPrediabetes with a history of myocardial infarction or unstable angina
Medical sciences (Basel, Switzerland)
Amnesia
upin humans1
1 study
Amnesia
upin humans1
Pravastatin is linked with a higher risk of amnesia in humans (ROR = 4.77, 95% CI: 3.76-6.06).
“pravastatin (n = 68, ROR = 4.77, 95% CI: 3.76-6.06, P < 0.001)”
Humansn = 68
Frontiers in pharmacology
Type 2 diabetes
upin humans1HR 1.19
1 study
Type 2 diabetes
upin humans1HR 1.19
Pravastatin is linked with a higher risk of type 2 diabetes in patients with established ASCVD on moderate-intensity statin therapy (HR 1.19, 95% CI 1.02-1.38).
“pravastatin (HR 1.19, 95% CI 1.02-1.38), and simvastatin (HR 1.15, 95% CI 1.06-1.20) were associated with higher NODM risk compared with atorvastatin”
Humansin patients with established ASCVD on moderate-intensity statin therapy
Frontiers in cardiovascular medicine
Cardiovascular disease
downin humans1RR 0.81
1 study
Cardiovascular disease
downin humans1RR 0.81
Pravastatin lowers the risk of cardiovascular disease in humans (RR = 0.81, 95% CI = 0.72-0.91).
“pravastatin significantly reduced the risks of total cardiovascular disease (RR = 0.81, 95% CI = 0.72-0.91)”
Review
Nutrients
Coronary artery disease
downin humans1
1 study
Coronary artery disease
downin humans1
Pravastatin lowers the risk of coronary artery disease in humans (10-year projection from parametric survival models) (+77.9 days CHD-free survival, 95% CI 3.8-159.6, p=.046).
“treated individuals would gain 77.9 days (95% CI=3.8-159.6, p=.046) of CHD-free survival”
Human trial10-year projection from parametric survival models40 mg/d10 years projectedn = 2,867
Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis
Journal of the American Geriatrics Society
Has pravastatin been tested in people?
6 of 95 about agingYes: 15 trials and 19 observational studies in people have been published, and 95 trials are registered.
About aging
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)
Phase 4Completed
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Phase 3Completed
Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)
Phase 2Completed
Phase 4Not yet recruiting
Phase 4Completed
Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease
Phase 4Completed
Approved
Oct 31, 1991Discontinued
Every condition in trials
Phase 4Results posted10 trials
Phase 4Completed7 trials
Hyperlipidemias
Phase 4Results posted7 trials
Phase 4Completed5 trials
Phase 4Completed4 trials
Phase 4Completed4 trials
40 of 74Fewer
Readouts due
- May 31, 2027
- Nov 2027
Stopped
NCT04385433TerminatedBreast neoplasm
Not enough patients enrolled
NCT03944512TerminatedPreeclampsia
participants are no longer being examined or receiving intervention
NCT00467831TerminatedAlbinism
insufficient enrollment
Who is developing pravastatin?
3 companies: Teva Pharmaceuticals USA, Mylan Pharmaceuticals and ViiV Healthcare.
Trial sponsors
Company5 trialsPhase 44,300 people
Company2 trialsPhase 4617 people
Mitsukoshi Health and Welfare Foundation
Company1 trialPhase 48,000 people
Company1 trialPhase 467 people
Company2 trialsPhase 3171 people
Company2 trialsPhase 360 people
Company4 trialsPhase 1158 people
Company2 trialsPhase 187 people
How this record changed
Summary written from the findings.